Telomere length variation: A potential new telomere biomarker for lung cancer risk.

Author: Sun B1, Wang Y1, Kota K1, Shi Y1, Motlak S1, Makambi K2, Loffredo CA2, Shields PG3, Yang Q4, Harris CC5, Zheng YL6.
Affiliation:
1Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States. 2Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, United States. 3James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH 43220, United States. 4Cancer Biology Division, Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, United States. 5Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States. 6Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States. Electronic address: yz37@georgetown.edu.
Conference/Journal: Lung Cancer.
Date published: 2015 Mar 20
Other: Pages: S0169-5002(15)00163-4 , Special Notes: doi: 10.1016/j.lungcan.2015.03.011 , Word Count: 238


Abstract
OBJECTIVES:
In this report the associations between telomere length variation (TLV), mean telomere length in blood lymphocytes and lung cancer risk were examined.
MATERIALS AND METHODS:
The study design is case-control. Cases (N=191) were patients newly diagnosed with histologically confirmed non-small cell lung cancer. Controls (N=207) were healthy individuals recruited from the same counties as cases and matched to cases on age and gender. Telomere fluorescent in situ hybridization was used to measure telomere features using short-term cultured blood lymphocytes. Logistic regression was used to estimate the strength of association between telomere features and lung cancer risk.
RESULTS:
Telomere length variation across all chromosomal ends was significantly associated with lung cancer risk; adjusted odds ratios 4.67 [95% confidence interval (CI): 1.46-14.9] and 0.46 (95% CI: 0.25-0.84) for younger (age≤60) and older (age>60) individuals, respectively. TLV and mean telomere length jointly affected lung cancer risk: when comparing individuals with short telomere length and high TLV to those with long telomere length and low TLV, adjusted odd ratios were 8.21 (95% CI: 1.71-39.5) and 0.33 (95% CI: 0.15-0.72) for younger and older individuals, respectively.
CONCLUSIONS:
TLV in blood lymphocytes is significantly associated with lung cancer risk and the associations were modulated by age. TLV in combination with mean telomere length might be useful in identifying high risk population for lung cancer computerized tomography screening.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
KEYWORDS:
Blood-based biomarker; Lung cancer; Risk prediction; Telomere dysfunction; Telomere length; Telomere length variation
PMID: 25840848

BACK